For the year ending 2025-12-31, SNDX made $172,352K in revenue. -$285,422K in net income. Net profit margin of -165.60%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Total revenue | 172,352 | 7,680 | ||
| Cost of product sales | 6,970 | 826 | ||
| Research and development expenses | 258,784 | 241,647 | ||
| Selling, general and administrative | 179,682 | 120,879 | ||
| Total operating expenses | 445,436 | 363,352 | ||
| Loss from operations | -273,084 | -339,672 | ||
| Royalty interest expense | 33,779 | - | ||
| Other interest (expense) income | 6 | 4,929 | ||
| Interest income | 22,730 | 26,090 | ||
| Other expense, net | -1,283 | -247 | ||
| Total other income | -12,338 | 20,914 | ||
| Net income | -285,422 | -318,758 | ||
| Basic EPS | -3.29 | -3.72 | ||
| Diluted EPS | -3.29 | -3.72 | ||
| Basic Average Shares | 86,625,610 | 85,622,065 | ||
| Diluted Average Shares | 86,625,610 | 85,622,065 | ||
Syndax Pharmaceuticals Inc (SNDX)
Syndax Pharmaceuticals Inc (SNDX)